
Eight sites actively recruiting patients for CYNK-001 COVID-19 therapy trial
December 4, 2020
Phase I/II studies to evaluate human placental hematopoietic stem cell–derived natural killer (NK) cell therapy to treat COVID-19 in hospitalized adults are currently ongoing as part of our partnership with the Infectious Disease Research Institute (IDRI).